These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36624752)

  • 1. Retrospective validation of bone risk stratification criteria for men with de novo metastatic hormone-naive prostate cancer in China.
    Zhang Y; Ding L; Zheng Y; Wang K; Xia W; Wang J; Ge P
    PeerJ; 2023; 11():e14500. PubMed ID: 36624752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a novel risk model in newly diagnosed
    Zhang Y; Wang J; Ding L; Zheng Y; Wu C; Wang K; Xia W; Ge P
    PeerJ; 2023; 11():e14615. PubMed ID: 36650836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
    Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
    Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.
    Nakanishi S; Goya M; Tamaki M; Oshiro T; Saito S
    BMC Res Notes; 2021 Jun; 14(1):227. PubMed ID: 34082809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer.
    Lim B; Lee W; Kyung YS; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):727-734. PubMed ID: 33948720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.
    Tsuzuki S; Kawano S; Fukuokaya W; Mori K; Nishikawa H; Tashiro K; Watanabe D; Uchimoto T; Nishimura K; Yano Y; Murakami M; Koike Y; Hata K; Koide H; Miki J; Abe H; Yamada H; Naruoka T; Sugaya S; Kimura T; Tomita M; Nakajo H; Egawa S
    Jpn J Clin Oncol; 2021 Nov; 51(11):1665-1671. PubMed ID: 34296282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial.
    Buelens S; Poelaert F; Dhondt B; Fonteyne V; De Visschere P; Ost P; Verbeke S; Villeirs G; De Man K; Rottey S; Decaestecker K; Lumen N
    Urol Oncol; 2018 Apr; 36(4):158.e13-158.e20. PubMed ID: 29336978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
    Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of Bone Scan Index (BSI) in the Prognosis and Treatment Efficacy in Castration-Sensitive Prostate Cancer Patients with Bone Metastasis].
    Deguchi K; Sasaki T; Oue H; Okamoto T; Kato M; Kajiwara S; Higashi S; Masui S; Nishikawa K; Inoue T
    Hinyokika Kiyo; 2024 Feb; 70(2):29-37. PubMed ID: 38447942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
    Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
    Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.
    Metwalli AR; Rosner IL; Cullen J; Chen Y; Brand T; Brassell SA; Lesperance J; Porter C; Sterbis J; McLeod DG
    Urol Oncol; 2014 Aug; 32(6):761-8. PubMed ID: 24929891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy.
    Huang H; Chen S; Li W; Bai P; Wu X; Xing J
    Clin Genitourin Cancer; 2019 Oct; 17(5):e1036-e1047. PubMed ID: 31281063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians.
    Sureka SK; Maheshwari R; Agnihotri S; Mitash N; Ahmad S; Mandhani A
    Indian J Med Res; 2016 May; 143(Supplement):S68-S73. PubMed ID: 27748280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
    Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
    Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy.
    Narita S; Nomura K; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nagashima K; Habuchi T
    Cancer Med; 2019 Nov; 8(15):6566-6577. PubMed ID: 31508900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.
    Miyoshi Y; Ohtaka M; Kawahara T; Ohtake S; Yasui M; Uemura K; Yoneyama S; Yokomizo Y; Uemura H; Miyamoto H; Yao M
    Urol Int; 2019; 102(1):37-42. PubMed ID: 30326476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
    Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
    Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.